Life Sciences Community,  

Colorado’s legislature is considering two bills related to the federal 340B Drug Pricing Program and both bills are expected to be debated on the Senate floor as early as Friday morning. Before that happens, we need you to tell legislators to put Colorado patients over hospital profits.  

The 340B program was originally intended to help low-income and uninsured patients access affordable medications by requiring drug manufacturers to provide discounts to safety-net providers. However, misuse and abuse of this well-intentioned but ballooning program is driving up costs for patients, taxpayers, employers, and everyone who pays for healthcare. 

If Colorado is going to consider establishing requirements related to 340B, it’s critical to start by demanding meaningful transparency and accountability (like in SB25-124) before even contemplating mandates (like in SB25-071) that would codify unchecked expansion of a program with little oversight or demonstrated benefit to patients. It’s bad policy to create new state mandates that expand this federal program before we even have full information about true costs and impacts of 340B. 

This is your opportunity to speak out and urge the Senate to:  

• Vote NO on SB25-071 Prohibit Restrictions on 340B Drugs, and 
• Vote YES on SB25-124 Reducing Costs of Health Care for Patients 

Colorado BioScience Association has been educating legislators about 340B and advocating on behalf of Colorado’s life sciences ecosystem and the patients we serve. Your support is critical to amplifying CBSA’s ongoing advocacy and lobbying work and to ensuring legislators prioritize patient-centered policy.  

Before Friday morning, please reach out to all State Senators or just your own (Find Your Legislator) using the sample email.

Thank you for joining the fight on this little-known but hugely impactful issue!